CSPC Pharmaceutical Group (HK:1093) has released an update.
CSPC Pharmaceutical Group Limited’s subsidiary, Shanghai JMT-BIO Technology Co., Ltd, has secured an exclusive license agreement with Jiangsu Alphamab to develop and commercialize a promising anti-tumor drug, JSKN003, in mainland China. The deal includes an upfront payment of RMB400 million, with potential milestone payments reaching up to RMB830 million, and sales milestones that could top RMB1.85 billion, along with double-digit percentage royalties on net sales.
For further insights into HK:1093 stock, check out TipRanks’ Stock Analysis page.
